Pulmonary manifestations of Gaucher disease - An increased risk for L444P homozygotes?

被引:43
作者
Santamaria, F
Parenti, G
Guidi, G
Filocamo, M
Strisciuglio, P
Grillo, G
Farina, V
Sarnelli, P
Rizzolo, MG
Rotondo, A
Andria, G
机构
[1] Univ Naples Federico II, Dept Pediat, I-80131 Naples, Italy
[2] Univ Naples Federico II, Dept Radiol, I-80131 Naples, Italy
[3] Ist Giannina Gaslini, Lab Diagnosi Pre Postnatale Malattie Metab, I-16148 Genoa, Italy
[4] Univ Bari, Inst Radiol, I-70121 Bari, Italy
[5] Univ Reggio Calabria, Dept Pediat, Catanzaro, Italy
关键词
D O I
10.1164/ajrccm.157.3.9706057
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Pulmonary disease is a complication of Gaucher disease (GD), a lysosomal disorder due to the deficiency of glucocerebrosidase. Lung involvement was investigated through chest radiography, high-resolution computed tomography of the chest, pulmonary function tests (PFT), and oxygen saturation (Sa(O2)) at 21% Fi(O2) in 13 Italian GD patients, six homoallelic for the L444P mutation (Group A), seven with various genotypes (Group B). Echocardiography and transcutaneous oxygen tension measurement at room air and after breathing 100% oxygen were performed to exclude pulmonary hypertension and/or intrapulmonary shunts. A score index (SI) including lung involvement evaluated the severity of GD. In three Group A patients with respiratory symptoms and in an asymptomatic male interstitial involvement was demonstrated; one child died of aspiration pneumonia. Group B patients had no signs of lung damage; PFT were normal in all cases but one. Sa(O2) was normal in both groups. Pulmonary vascular disease was ruled out in three cases with respiratory symptoms. In Groups A and B the median SI were 22 and 13, respectively (p < 0.01). L444P homozygotes appear at major risk for developing pulmonary disease, even at earlier ages. A comprehensive evaluation of lung involvement is recommended primarily in these subjects.
引用
收藏
页码:985 / 989
页数:5
相关论文
共 20 条
[1]   GAUCHERS-DISEASE VARIANT CHARACTERIZED BY PROGRESSIVE CALCIFICATION OF HEART-VALVES AND UNIQUE GENOTYPE [J].
ABRAHAMOV, A ;
ELSTEIN, D ;
GROSSTSUR, V ;
FARBER, B ;
GLASER, Y ;
HADASHALPERN, I ;
RONEN, S ;
TAFAKJDI, M ;
HOROWITZ, M ;
ZIMRAN, A .
LANCET, 1995, 346 (8981) :1000-1003
[2]  
[Anonymous], LUNG FUNCTION ASSESS
[3]   CARDIORESPIRATORY FAILURE IN KYPHOSCOLIOSIS [J].
BERGOFSKY, EH ;
TURINO, GM ;
FISHMAN, AP .
MEDICINE, 1959, 38 (03) :263-317
[4]  
Beutler E., 1995, METABOLIC MOL BASES, P2641
[5]   THE ROLE OF NEUROGENETICS IN GAUCHER DISEASE [J].
BRADY, RO ;
BARTON, NW ;
GRABOWSKI, GA .
ARCHIVES OF NEUROLOGY, 1993, 50 (11) :1212-1224
[6]   AN IMPROVED FLUOROMETRIC LEUKOCYTE BETA-GLUCOSIDASE ASSAY FOR GAUCHERS-DISEASE [J].
DANIELS, LB ;
GLEW, RH ;
DIVEN, WF ;
LEE, RE ;
RADIN, NS .
CLINICA CHIMICA ACTA, 1981, 115 (03) :369-375
[7]   Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome [J].
Dawson, A ;
Elias, DJ ;
Rubenson, D ;
Bartz, SH ;
Garver, PR ;
Kay, AC ;
Bloor, CM ;
Beutler, E .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (11) :901-904
[8]  
FERRIS BG, 1978, AM REV RESPIR DIS S, V118, P36
[9]   Pulmonary function abnormalities in type I Gaucher disease [J].
Kerem, E ;
Elstein, D ;
Abrahamov, A ;
Ziv, YB ;
HadasHalpern, I ;
Melzer, E ;
Cahan, C ;
Branski, D ;
Zimran, A .
EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (02) :340-345
[10]  
KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587